Willis, Mark ORCID: https://orcid.org/0000-0003-3024-6063, Pickersgill, Trevor, Robertson, Neil ORCID: https://orcid.org/0000-0002-5409-4909, Lee, Richard W. J., Dick, Andrew D. and Carreño, Ester 2016. Alemtuzumab-induced remission of multiple sclerosis-associated uveitis. International Ophthalmology 10.1007/s10792-016-0370-9 |
Preview |
PDF
- Accepted Post-Print Version
Download (288kB) | Preview |
Abstract
Purpose The purpose of the study was to report a case of multiple sclerosis (MS)-associated uveitis refractory to conventional immunosuppressants, with subsequent remission following treatment with alemtuzumab. Methods Case report Patient was treated with intravenous alemtuzumab, a lymphocyte depleting anti-CD52 monoclonal antibody that has recently been approved for use in relapsing MS. Results A 17-year-old female presented with bilateral optic neuritis and subsequently bilateral intermediate uveitis and secondary macular oedema. She was diagnosed with active relapsing MS for which she received treatment with alemtuzumab. The intraocular inflammation previously refractory to conventional immunosuppressants responded to alemtuzumab, inducing remission. Conclusions To our knowledge, this is the first such report of alemtuzumab treatment in MS-associated ocular inflammatory disease and may demonstrate a potential utility for this drug in related conditions.
Item Type: | Article |
---|---|
Date Type: | Published Online |
Status: | Published |
Schools: | Medicine MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG) |
Subjects: | R Medicine > R Medicine (General) |
Uncontrolled Keywords: | Multiple sclerosisUveitisAlemtuzumabIntraocular inflammation |
Publisher: | Springer Verlag |
ISSN: | 0165-5701 |
Date of First Compliant Deposit: | 14 December 2016 |
Date of Acceptance: | 29 September 2016 |
Last Modified: | 24 Nov 2024 08:45 |
URI: | https://orca.cardiff.ac.uk/id/eprint/96900 |
Citation Data
Cited 6 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
Edit Item |